Why the study?
Little is known about North American encephalomyocarditis virus diversity, reservoir hosts, and zoo outbreak epidemiology, which has impeded understanding how genetic and antigenic variation affects pathogenicity and vaccine protection.
Does an autogenous vaccine induce long-term neutralizing antibody responses and cross-protection against divergent EMCV strains in elephants?
Population
Fatal zoo animal cases, local rodent species, and elephants following an outbreak in Florida
Comparison
Autogenous vaccine evaluation across divergent strains and serotypes
Design
Comparative phylogenomic, longitudinal serologic, and reverse genetics study
Follow-up
Monthly for multiple years
Key result
Autogenous EMCV vaccination in elephants elicited long-term neutralizing antibodies, with cross-protection confirmed against diverse EMCV strains via reverse genetics.
Authors
Loading...
May guide EMCV vaccination in captive elephants; leaves open field validation and translation to other species.
Does an autogenous vaccine induce long-term neutralizing antibody responses and cross-protection against divergent EMCV strains in elephants?
This study provides a comprehensive phylogenomic analysis of EMCV transmission in Florida and demonstrates the long-term neutralizing antibody response and cross-protection of an autogenous vaccine in elephants.
Adhikari et al. (2026) studied this question. Autogenous EMCV vaccination in elephants elicited long-term neutralizing antibodies, with cross-protection confirmed against diverse EMCV strains via reverse genetics.